Health · Approval
FDA Approves First Factor XIa Pill to Cut Repeat Strokes in Survivors
Bayer’s asundexian, sold as Sunharbo, is a once-daily tablet added to antiplatelet therapy. It is not approved for strokes caused by atrial fibrillation.

The Food and Drug Administration approved Bayer’s asundexian, sold as Sunharbo, on Nov. 9 for adults who recently had a mild-to-moderate ischemic stroke not caused by a heart clot, or a high-risk mini-stroke, the American Journal of Managed Care reported. It is the first Factor XIa inhibitor cleared for the purpose. Patients take one 50 mg tablet daily alongside antiplatelet therapy such as aspirin.
The approval rests on OCEANIC-STROKE, a Bayer-funded trial of 12,327 patients. The drug cut the relative risk of ischemic stroke by 26 percent over a median of 14.2 months. Fox News reported rates of about 6.6 percent on the drug versus 8.8 percent on placebo.
Major bleeding did not rise significantly overall, but it was higher in patients over 75 and in the first 90 days, and gastrointestinal bleeding was more common. The drug is not approved for strokes tied to atrial fibrillation. Cardiologist Dr. Richard Kovacs told Fox News the pill “doesn’t completely eliminate” the chance of another stroke. No U.S. price or launch date was reported.
Sources
- American Journal of Managed Care, Nov. 10, 2026: FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke <https://www.ajmc.com/view/fda-approves-asundexian-first-fxia-inhibitor-to-prevent-repeat-stroke>
- Pharmaceutical Executive, Nov. 10, 2026: FDA Approves asundexian for Secondary Stroke Risk Reduction <https://www.pharmexec.com/view/fda-approves-asundexian-for-secondary-stroke-risk-reduction>
- Fox News, Nov. 14, 2026: Stroke survivors get FDA-approved daily pill shown to cut repeat risk by 26% <https://www.foxnews.com/health/stroke-survivors-get-fda-approved-daily-pill-shown-cut-repeat-risk>
This article was drafted with AI writing tools from the sources listed, checked by a review pass, supervised by the paper’s editors and published by Daniel Varrone. Corrections: editor@monochromechronicles.com
More from Health
Recommended Reading
About this story: Compiled by the The Monochrome Chronicles desk from the sources listed above. Our standards · Report an error · Follow on YouTube